Compare FuelCell Energy Inc (FCEL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Inovio Pharmaceuticals Inc — how do they compare? FuelCell Energy Inc trades at $18 (market cap $1.47B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M). The key difference: FuelCell Energy Inc is far larger — about 13.1× Inovio Pharmaceuticals Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FCEL | INO | |
|---|---|---|
Market Cap | $1.47B | $112.19M |
Volume | 12,559,948 | 3,201,278 |
Sector | Industrials | Health |
52-Week High | $36.01 | $2.65 |
52-Week Low | $6.00 | $0.66 |
Typical Hold Time | 48 Days | 43 Days |
Enterprise Value | $1.05B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $17.29, down 5.85% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported revenue of $158.16M for 2025 but posted a net loss of $187.90M, with negative gross and net income margins. Recent news highlights a securities class action lawsuit and a 7% stock rally amid hydrogen sector interest.
The outlook remains cautious due to persistent losses and legal risks, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include profitability challenges and competitive pressures in the clean energy sector, while potential upside hinges on execution improvements and sector momentum.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
